$INTI
Inhibitor Therapeutics, Inc.

2017 Q4 Form 10-Q Financial Statement

#000119312517326046 Filed on October 31, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $370.0K $250.0K $1.010M
YoY Change -81.77% -75.25% 68.33%
% of Gross Profit
Research & Development $530.0K $433.5K $720.3K
YoY Change -27.4% -39.81% 19.72%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $910.0K $681.2K $1.734M
YoY Change -67.03% -60.72% 44.27%
Operating Profit -$681.2K -$1.734M
YoY Change -60.72% 44.27%
Interest Expense $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$900.0K -$680.0K -$1.730M
YoY Change -67.27% -60.69% 44.17%
Income Tax
% Of Pretax Income
Net Earnings -$900.0K -$679.1K -$1.725M
YoY Change -67.27% -60.63% 43.5%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 $0.00 -$0.01
COMMON SHARES
Basic Shares Outstanding 369.6M shares 369.6M shares 300.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $340.0K $890.0K $3.550M
YoY Change -95.07% -74.93% 186.29%
Cash & Equivalents $344.1K $887.4K $3.554M
Short-Term Investments
Other Short-Term Assets $310.0K $300.0K $58.90K
YoY Change 0.0% 409.3% -1.83%
Inventory
Prepaid Expenses $61.66K $51.95K
Receivables
Other Receivables
Total Short-Term Assets $655.8K $1.189M $3.613M
YoY Change -90.89% -67.08% 177.93%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $112.3K $119.6K $250.0K
YoY Change -20.69% -52.16% 0.0%
Total Long-Term Assets $112.3K $119.6K $250.0K
YoY Change -20.69% -52.16% 0.0%
TOTAL ASSETS
Total Short-Term Assets $655.8K $1.189M $3.613M
Total Long-Term Assets $112.3K $119.6K $250.0K
Total Assets $768.1K $1.309M $3.863M
YoY Change -89.53% -66.11% 149.23%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $535.0K $218.7K $441.5K
YoY Change 79.62% -50.47% -0.14%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $601.5K $252.2K $469.6K
YoY Change 95.2% -46.29% -13.1%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $601.5K $252.2K $469.6K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $601.5K $252.2K $469.6K
YoY Change 95.2% -46.29% -13.1%
SHAREHOLDERS EQUITY
Retained Earnings -$48.27M -$47.37M -$40.42M
YoY Change 11.82% 17.19% 15.03%
Common Stock $48.44M $48.43M $43.81M
YoY Change -3.51% 10.53% 21.2%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $166.6K $1.057M $3.393M
YoY Change
Total Liabilities & Shareholders Equity $768.1K $1.309M $3.863M
YoY Change -89.53% -66.11% 149.23%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income -$900.0K -$679.1K -$1.725M
YoY Change -67.27% -60.63% 43.5%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$540.0K -$760.0K -$1.060M
YoY Change -55.37% -28.3% 63.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -540.0K -760.0K -1.060M
Cash From Investing Activities
Cash From Financing Activities 0.000 0.000 0.000
Net Change In Cash -540.0K -760.0K -1.060M
YoY Change -116.22% -28.3% 63.08%
FREE CASH FLOW
Cash From Operating Activities -$540.0K -$760.0K -$1.060M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3553832
CY2017Q3 us-gaap Assets Current
AssetsCurrent
1189315
CY2017Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
48389463
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
218663
CY2017Q3 us-gaap Assets
Assets
1308922
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
887361
CY2017Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
400000
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
369599266 shares
CY2017Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
369599266 shares
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
36960
CY2017Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2017Q3 us-gaap Liabilities
Liabilities
252202
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1308922
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
252202
CY2017Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
33539
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
119607
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
650000 shares
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
1056720
CY2017Q3 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
369599266 shares
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
51954
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47369703
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
100000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
601445
CY2016Q4 us-gaap Assets Current
AssetsCurrent
7196519
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
50167372
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
297826
CY2016Q4 us-gaap Assets
Assets
7338095
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6885422
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
353447172 shares
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
353447172 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
35345
CY2016Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
250000
CY2016Q4 us-gaap Liabilities
Liabilities
308133
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7338095
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
308133
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
10307
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
141576
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
61097
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43172755
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
7029962
CY2016Q4 hppi Percentage Of Deferred Tax Assets Valuation Allowance
PercentageOfDeferredTaxAssetsValuationAllowance
1.00 pure
dei Amendment Flag
AmendmentFlag
false
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
1851933
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
49500
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5998061
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001042418
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2521029
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-55931
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-31112
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
16726
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2369834
us-gaap Operating Expenses
OperatingExpenses
4213674
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-3628227
us-gaap Net Income Loss
NetIncomeLoss
-4196948
us-gaap Operating Income Loss
OperatingIncomeLoss
-4213674
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1908372
us-gaap Revenues
Revenues
0
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2350337
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7723
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
24490
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
10230
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2548937
us-gaap Operating Expenses
OperatingExpenses
4258709
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5501324
us-gaap Net Income Loss
NetIncomeLoss
-4248479
us-gaap Operating Income Loss
OperatingIncomeLoss
-4258709
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2664900
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1692645
us-gaap Revenues
Revenues
0
us-gaap Share Based Compensation
ShareBasedCompensation
1851933
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3677727
dei Trading Symbol
TradingSymbol
HPPI
us-gaap Valuation Allowance Methodologies And Assumptions
ValuationAllowanceMethodologiesAndAssumptions
In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence it is more likely than not that some portion or all of the deferred tax assets will not be realized. At September 30, 2017 and December 31, 2016, the Company recorded a 100% valuation allowance against its deferred tax assets as it has determined such amounts will not be currently realizable.
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
365618815 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
hppi Net Settlement In Connection With Issuance Of Shares Associated With Restricted Stock Units
NetSettlementInConnectionWithIssuanceOfSharesAssociatedWithRestrictedStockUnits
3677727
hppi Fair Value Of Shares Withheld With Net Settlement Transaction
FairValueOfSharesWithheldWithNetSettlementTransaction
3677727
hppi Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
49500
hppi Percentage Of Target Tumors Controlled
PercentageOfTargetTumorsControlled
0.99 pure
hppi Percentage Of Reduction In Size Of Thirty Percent Or Greater Since Dosing Began
PercentageOfReductionInSizeOfThirtyPercentOrGreaterSinceDosingBegan
0.54 pure
hppi Percentage Of Target Tumor Completely Disappeared
PercentageOfTargetTumorCompletelyDisappeared
0.28 pure
hppi Percentage Of Target Tumor Continued To Respond During Ongoing Treatment
PercentageOfTargetTumorContinuedToRespondDuringOngoingTreatment
0.60 pure
hppi Percentage Of Patient Dropout Rate
PercentageOfPatientDropoutRate
0.11 pure
hppi Number Of Individuals Measured For Target Tumors Response
NumberOfIndividualsMeasuredForTargetTumorsResponse
467 pure
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2952387
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Share Based Compensation
ShareBasedCompensation
1716309
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
273979411 shares
hppi Proceeds From Issuance Of Common Stock Related Parties
ProceedsFromIssuanceOfCommonStockRelatedParties
2836424
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1013846
CY2016Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
9177
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
1734185
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-1725008
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1734185
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
720339
CY2016Q3 us-gaap Revenues
Revenues
0
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
300353270 shares
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
247621
CY2017Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2086
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
681166
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-679080
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-681166
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
433545
CY2017Q3 us-gaap Revenues
Revenues
0
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
369599266 shares

Files In Submission

Name View Source Status
0001193125-17-326046-index-headers.html Edgar Link pending
0001193125-17-326046-index.html Edgar Link pending
0001193125-17-326046.txt Edgar Link pending
0001193125-17-326046-xbrl.zip Edgar Link pending
d335642d10q.htm Edgar Link pending
d335642dex311.htm Edgar Link pending
d335642dex312.htm Edgar Link pending
d335642dex321.htm Edgar Link pending
d335642dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
hppi-20170930.xml Edgar Link completed
hppi-20170930.xsd Edgar Link pending
hppi-20170930_cal.xml Edgar Link unprocessable
hppi-20170930_def.xml Edgar Link unprocessable
hppi-20170930_lab.xml Edgar Link unprocessable
hppi-20170930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending